All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
The FDA grants GMI-1271 Breakthrough Therapy Designation for the treatment of R/R AML
On 17th March 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to GMI-1271, a novel E-selectin (E-sel) antagonist , for the treatment of patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).1
E-sel is a cell adhesion molecule expressed constitutively in the bone marrow endothelium and it is involved in cell signaling and chemotaxis. Binding of AML blasts to E-selectin (E-sel), can lead to activation of leukemic cell survival pathways, thereby contributing to chemotherapy resistance. GMI-1271 is a novel antagonist of E-sel, which acts by disrupting leukemia cell survival pathways thus enhancing chemotherapy response.2,3
Currently, GMI-1271 is being explored in the phase 2 portion of the phase 1/2 study (NCT02306291), which is aiming to assess the safety, efficacy and pharmacokinetics of this agent in combination with standard chemotherapy in patients with R/R AML and also in AML patients 60 years of age and older with newly diagnosed disease.
References